Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248857 | 1.00 | CASP3 (0.38) | CASP3ACEROCK2EPHX2PARP1 | |
| SCHEMBL10565831 | 0.84 | ACE (0.44) | CASP3ACEROCK2EPHX2PARP1 | |
| SCHEMBL644711 | 0.82 | ACE (0.40) | CASP3ACEROCK2PARP1HSD17B10 | |
| SCHEMBL949749 | 0.82 | ACE (0.40) | CASP3ACEROCK2PARP1HSD17B10 | |
| SCHEMBL949486 | 0.79 | CASP3 (0.39) | CASP3ROCK2EPHX2PARP1HSD17B10 | |
| SCHEMBL949485 | 0.79 | CASP3 (0.39) | CASP3ROCK2EPHX2PARP1HSD17B10 | |
| SCHEMBL10201276 | 0.78 | CASP3 (0.39) | CASP3ROCK2EPHX2PARP1HSD17B10 | |
| SCHEMBL10248861 | 0.78 | CASP3 (0.39) | CASP3ROCK2EPHX2PARP1HSD17B10 | |
| SCHEMBL11108799 | 0.77 | CASP3 (0.39) | CASP3ACEROCK2EPHX2HSD17B10 | |
| SCHEMBL11113201 | 0.77 | ACE (0.39) | CASP3ACEROCK2EPHX2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP3 85/4885ACE 16/4885ROCK2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.